JOURNAL OF INFECTIOUS DISEASES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2023-09-06 ms1000000935651063 来自湖北省

偏重的研究方向：传染病
经验分享：这本杂志with editor多久啊，投了半个月了还是with editor

26 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2021-12-29 学医的彭于晏

引言中文章的创新性如何体现？

72 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2021-12-27 学医的彭于晏

引言需要写什么内容？

70 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2019-04-04 ms8480212230682571

审稿速度:6.0 | 投稿命中率:25.0
经验分享：reviwer 的意见比较详细，认真回答后已录用。

161 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2020-04-13 1248071em52(暂无昵称)

请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表::
的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表:
的确.最终出版时只能一个通讯.我已经在之前评论回复过了!

wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!

199 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2019-06-03 For you

这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?

210 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2021-06-12 嗷大喵haha

Jun 08, 2021提交的，10号送审的，期待审稿意见

111 0

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2020-03-06 146f6ef6m90(暂无昵称)

即时4.77

202 0

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2020-02-23 huxiaoyan

接收个案吗？

175 0

[GetPortalCommentsPageByObjectIdResponse(id=2156407, encodeId=0624215640ed5, content=偏重的研究方向：传染病 经验分享：这本杂志with editor多久啊，投了半个月了还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13545726588, createdName=ms1000000935651063, createdTime=Wed Sep 06 16:44:39 CST 2023, time=2023-09-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1093398, encodeId=8ba0109339823, content=引言中文章的创新性如何体现？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093397, encodeId=3a12109339e08, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850642, encodeId=8aac85064270, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：reviwer 的意见比较详细，认真回答后已录用。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Apr 04 02:40:14 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588753, encodeId=8784588e53d4, content=请问现在还是只允许一个通讯作者吗？指南里没看到，投稿快一个月，还是Review wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!wmw90 2017-09-03 00:00:00 发表: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, beContent=wmw90 2017-09-03 发表:: 的确.最终出版时只能一个通讯.我已经在之前评论回复过了!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b932492674, createdName=1248071em52(暂无昵称), createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571839, encodeId=e9435e1839dd, content=这个期刊是不是改过刊名？原来是不是叫Immunology and infectious diseases?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/03/bf0b0998ee22e7517060d91fd92e0c7e.jpg, createdBy=0a1e2036775, createdName=For you, createdTime=Mon Jun 03 00:00:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973130, encodeId=69969e3130eb, content=Jun 08, 2021提交的，10号送审的，期待审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5f71952119, createdName=嗷大喵haha, createdTime=Sat Jun 12 18:49:14 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585997, encodeId=d6c558599e60, content=即时4.77, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Fri Mar 06 00:00:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585240, encodeId=f6df585240a5, content=接收个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a1b2139348, createdName=huxiaoyan, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848305, encodeId=d77d848305e6, content=非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24c85414030, createdName=ms7686472318774529, createdTime=Thu Nov 22 09:38:29 CST 2018, time=2018-11-22, status=1, ipAttribution=)]

2018-11-22 ms7686472318774529

非常好的杂志，虽然被拒。投稿之后很快编辑就决定送审，大概一个月后，两个外审意见已拿到。可能是自己文章写得太差了，主编最终拒稿。但审稿人意见还是挺不错的。对于文章的修改有很大帮助

173 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务